- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- 14 Nov 23 EFFECT Notice of effectiveness
- 8 Nov 23 S-4/A Registration of securities issued in business combination transactions (amended)
- 18 Oct 23 S-4/A Registration of securities issued in business combination transactions (amended)
- 28 Sep 23 S-4/A Registration of securities issued in business combination transactions (amended)
-
18 Aug 23 S-4 Registration of securities issued in business combination transactions
- 8 Nov 23 Registration of securities issued in business combination transactions (amended)
- 18 Oct 23 Registration of securities issued in business combination transactions (amended)
- 28 Sep 23 Registration of securities issued in business combination transactions (amended)
- 18 Aug 23 Registration of securities issued in business combination transactions
Exhibit 99.4
Rohan Palekar
c/o Neoleukin Therapeutics, Inc.
188 East Blaine Street, Suite 450
Seattle, Washington 98102
Consent to Reference in Proxy Statement/Prospectus
Neoleukin Therapeutics, Inc. is filing a Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to the reference to me in the proxy statement/prospectus included in such registration statement as a future member of the board of directors of the combined company following the consummation of the merger. I also consent to the filing of this consent as an exhibit to the Registration Statement.
Sincerely,
/s/ Rohan Palekar |
Name: Rohan Palekar |